Novel Therapies Boosting T Cell Immunity ...
Type de document :
Compte-rendu et recension critique d'ouvrage
DOI :
Titre :
Novel Therapies Boosting T Cell Immunity in Epstein Barr Virus-Associated Nasopharyngeal Carcinoma
Auteur(s) :
Renaud, Sarah [Auteur]
Thérapies Laser Assistées par l'Image pour l'Oncologie - U 1189 [ONCO-THAI]
Institut de biologie de Lille - UMS 3702 [IBL]
Lefebvre, Anthony [Auteur]
Thérapies Laser Assistées par l'Image pour l'Oncologie - U 1189 [ONCO-THAI]
Mordon, Serge [Auteur]
Thérapies Laser Assistées par l'Image pour l'Oncologie - U 1189 [ONCO-THAI]
Institut National de la Santé et de la Recherche Médicale [INSERM]
Université de Lille
Morales, Olivier [Auteur]
Thérapies Laser Assistées par l'Image pour l'Oncologie - U 1189 [ONCO-THAI]
Delhem, Nadira [Auteur]
Thérapies Laser Assistées par l'Image pour l'Oncologie - U 1189 [ONCO-THAI]
Thérapies Laser Assistées par l'Image pour l'Oncologie - U 1189 [ONCO-THAI]
Institut de biologie de Lille - UMS 3702 [IBL]
Lefebvre, Anthony [Auteur]
Thérapies Laser Assistées par l'Image pour l'Oncologie - U 1189 [ONCO-THAI]
Mordon, Serge [Auteur]
Thérapies Laser Assistées par l'Image pour l'Oncologie - U 1189 [ONCO-THAI]
Institut National de la Santé et de la Recherche Médicale [INSERM]
Université de Lille
Morales, Olivier [Auteur]
Thérapies Laser Assistées par l'Image pour l'Oncologie - U 1189 [ONCO-THAI]
Delhem, Nadira [Auteur]
Thérapies Laser Assistées par l'Image pour l'Oncologie - U 1189 [ONCO-THAI]
Titre de la revue :
International Journal of Molecular Sciences
Pagination :
4292
Éditeur :
MDPI
Date de publication :
2020
ISSN :
1661-6596
Mot(s)-clé(s) en anglais :
therapy
T cell
immunity
EBV
nasopharyngeal carcinoma
T cell
immunity
EBV
nasopharyngeal carcinoma
Discipline(s) HAL :
Sciences du Vivant [q-bio]/Cancer
Sciences du Vivant [q-bio]/Immunologie/Immunothérapie
Sciences du Vivant [q-bio]/Immunologie/Immunothérapie
Résumé en anglais : [en]
Nasopharyngeal carcinoma (NPC) is a malignant tumour of the head and neck affecting localised regions of the world, with the highest rates described in Southeast Asia, Northern Africa, and Greenland. Its high morbidity ...
Lire la suite >Nasopharyngeal carcinoma (NPC) is a malignant tumour of the head and neck affecting localised regions of the world, with the highest rates described in Southeast Asia, Northern Africa, and Greenland. Its high morbidity rate is linked to both late-stage diagnosis and unresponsiveness to conventional anti-cancer treatments. Multiple aetiological factors have been described including environmental factors, genetics, and viral factors (Epstein Barr Virus, EBV), making NPC treatment that much more complex. The most common forms of NPCs are those that originate from the epithelial tissue lining the nasopharynx and are often linked to EBV infection. Indeed, they represent 75-95% of NPCs in the low-risk populations and almost 100% of NPCs in high-risk populations. Although conventional surgery has been improved with nasopharyngectomy's being carried out using more sophisticated surgical equipment for better tumour resection, recent findings in the tumour microenvironment have led to novel treatment options including immunotherapies and photodynamic therapy, able to target the tumour and improve the immune system. This review provides an update on the disease's aetiology and the future of NPC treatments with a focus on therapies activating T cell immunity.Lire moins >
Lire la suite >Nasopharyngeal carcinoma (NPC) is a malignant tumour of the head and neck affecting localised regions of the world, with the highest rates described in Southeast Asia, Northern Africa, and Greenland. Its high morbidity rate is linked to both late-stage diagnosis and unresponsiveness to conventional anti-cancer treatments. Multiple aetiological factors have been described including environmental factors, genetics, and viral factors (Epstein Barr Virus, EBV), making NPC treatment that much more complex. The most common forms of NPCs are those that originate from the epithelial tissue lining the nasopharynx and are often linked to EBV infection. Indeed, they represent 75-95% of NPCs in the low-risk populations and almost 100% of NPCs in high-risk populations. Although conventional surgery has been improved with nasopharyngectomy's being carried out using more sophisticated surgical equipment for better tumour resection, recent findings in the tumour microenvironment have led to novel treatment options including immunotherapies and photodynamic therapy, able to target the tumour and improve the immune system. This review provides an update on the disease's aetiology and the future of NPC treatments with a focus on therapies activating T cell immunity.Lire moins >
Langue :
Anglais
Vulgarisation :
Non
Source :
Fichiers
- https://hal.archives-ouvertes.fr/hal-02875212v2/document
- Accès libre
- Accéder au document
- https://hal.archives-ouvertes.fr/hal-02875212v2/document
- Accès libre
- Accéder au document
- https://hal.archives-ouvertes.fr/hal-02875212v2/document
- Accès libre
- Accéder au document
- document
- Accès libre
- Accéder au document
- Novel%20Therapies%20Boosting%20T%20Cell%20Immunity%20in%20Epstein%20Barr%20Virus-Associated%20Nasopharyngeal%20Carcinoma%20%281%29.pdf
- Accès libre
- Accéder au document
- Accès libre
- Accéder au document